BioLineRXBLRX
About: BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Employees: 79
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1,500% more call options, than puts
Call options by funds: $16K | Put options by funds: $1K
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
0.06% less ownership
Funds ownership: 0.21% [Q3] → 0.15% (-0.06%) [Q4]
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
3% less funds holding
Funds holding: 32 [Q3] → 31 (-1) [Q4]
67% less capital invested
Capital invested by funds: $1.34M [Q3] → $439K (-$904K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for BLRX.
Financial journalist opinion









